Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Portfolio Pulse from
Xenetic Biosciences, Inc. presented positive preclinical data at the SITC Spring Scientific 2025 Cell Therapy Meeting, highlighting the potential of DNase I to enhance immunotherapeutic responses by degrading neutrophil extracellular traps, thus improving T cell infiltration and functionality in cancer treatments.
March 13, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenetic Biosciences presented promising preclinical data on DNase I, showing potential to enhance CAR-T cell therapy by targeting neutrophil extracellular traps, which could lead to more effective cancer treatments.
The presentation of positive preclinical data at a major scientific meeting suggests potential advancements in cancer treatment, which could positively impact Xenetic's stock price. The focus on enhancing CAR-T cell therapy is significant for investors interested in innovative cancer treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100